Radiosensitivity of Cancer Cells Is Regulated by Translationally Controlled Tumor Protein
- PMID: 30893896
- PMCID: PMC6468585
- DOI: 10.3390/cancers11030386
Radiosensitivity of Cancer Cells Is Regulated by Translationally Controlled Tumor Protein
Abstract
Translationally controlled tumor protein (TCTP) is a ubiquitous multifunctional protein that is essential for cell survival. This study reveals that the regulation of radiosensitivity of cancer cells is yet another function of TCTP. The relationship between endogenous TCTP levels and sensitivity to radiation was examined in breast cancer cell lines (T47D, MDA-MB-231, and MCF7) and lung cancer cells lines (A549, H1299, and H460). Cancer cells with high expression levels of TCTP were more resistant to radiation. TCTP overexpression inhibited radiation-induced cell death, while silencing TCTP led to an increase in radiosensitivity. DNA damage in the irradiated TCTP-silenced A549 cells was greater than in irradiated control shRNA-transfected A549 cells. p53, a well-known reciprocal regulator of TCTP, was increased in irradiated TCTP down-regulated A549 cells. Moreover, introduction of p53 siRNA in TCTP knocked-down A549 cells abrogated the increased radiosensitivity induced by TCTP knockdown. An in vivo xenograft study also confirmed enhanced radiosensitivity in TCTP down-regulated A549 cells. These findings suggest that TCTP has the potential to serve as a therapeutic target to overcome radiation resistance in cancer, a major problem for the effective treatment of cancers.
Keywords: TCTP; p53; radioresistance.
Conflict of interest statement
The authors declare no conflict of interest.
Figures







Similar articles
-
Knockdown of translationally controlled tumor protein inhibits growth, migration and invasion of lung cancer cells.Life Sci. 2018 Jan 15;193:292-299. doi: 10.1016/j.lfs.2017.09.039. Epub 2017 Sep 29. Life Sci. 2018. PMID: 28970113
-
Dcr3 inhibit p53-dependent apoptosis in gamma-irradiated lung cancer cells.Int J Radiat Biol. 2010 Sep;86(9):780-90. doi: 10.3109/09553002.2010.484481. Int J Radiat Biol. 2010. PMID: 20597837
-
Aberrant expression of translationally controlled tumor protein (TCTP) can lead to radioactive susceptibility and chemosensitivity in lung cancer cells.Oncotarget. 2017 Oct 10;8(60):101922-101935. doi: 10.18632/oncotarget.21747. eCollection 2017 Nov 24. Oncotarget. 2017. PMID: 29254214 Free PMC article.
-
The Translationally Controlled Tumor Protein and the Cellular Response to Ionizing Radiation-Induced DNA Damage.Results Probl Cell Differ. 2017;64:227-253. doi: 10.1007/978-3-319-67591-6_12. Results Probl Cell Differ. 2017. PMID: 29149412 Review.
-
TCTP as therapeutic target in cancers.Cancer Treat Rev. 2014 Jul;40(6):760-9. doi: 10.1016/j.ctrv.2014.02.007. Epub 2014 Mar 2. Cancer Treat Rev. 2014. PMID: 24650927 Review.
Cited by
-
GATA3 Exerts Distinct Transcriptional Functions to Regulate Radiation Resistance in A549 and H1299 Cells.Oxid Med Cell Longev. 2022 Aug 10;2022:9174111. doi: 10.1155/2022/9174111. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35993027 Free PMC article.
-
Electron Attachment Studies with the Potential Radiosensitizer 2-Nitrofuran.Int J Mol Sci. 2020 Nov 24;21(23):8906. doi: 10.3390/ijms21238906. Int J Mol Sci. 2020. PMID: 33255344 Free PMC article.
-
Biological role and expression of translationally controlled tumor protein (TCTP) in tumorigenesis and development and its potential for targeted tumor therapy.Cancer Cell Int. 2024 Jun 4;24(1):198. doi: 10.1186/s12935-024-03355-9. Cancer Cell Int. 2024. PMID: 38835077 Free PMC article. Review.
-
Regulation of Autophagy Is a Novel Tumorigenesis-Related Activity of Multifunctional Translationally Controlled Tumor Protein.Cells. 2020 Jan 20;9(1):257. doi: 10.3390/cells9010257. Cells. 2020. PMID: 31968668 Free PMC article. Review.
-
Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors.Cancers (Basel). 2022 Apr 28;14(9):2202. doi: 10.3390/cancers14092202. Cancers (Basel). 2022. PMID: 35565331 Free PMC article. Review.
References
-
- Harrington K.J., Billingham L.J., Brunner T.B., Burnet N.G., Chan C.S., Hoskin P., Mackay R.I., Maughan T.S., Macdougall J., McKenna W.G., et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br. J. Cancer. 2011;105:628–639. doi: 10.1038/bjc.2011.240. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous